1. bluebird bio. Our science: what is gene therapy? 2021. https://www.bluebirdbio.com/our-science/what-is-gene-therapy. Accessed 19 July 2021.
2. European Medicines Agency. Skysona (elivaldogene autotemcel): EU summary of product characteristics. 2021. https://www.ema.europa.eu/. Accessed 26 July 2021.
3. bluebird bio. Fom 10-K. 2021. https://investor.bluebirdbio.com/static-files/a0cfdff2-2784-4e01-9237-8be586e10bce. Accessed 7 July 2021.
4. Federico A, de Visser M. New disease modifying therapies for two genetic childhood-onset neurometabolic disorders (metachromatic leucodystrophy and adrenoleucodystrophy). Neurol Sci. 2021;42(7):2603–6.
5. Musolino P, Lauer A, Choi M, et al. Lenti-D gene therapy attenuates microvascular perfusion abnormalities and halts cerebral adrenoleukodystrophy lesion progression [abstract no. 156]. Ann Neurol. 2019;86(Suppl 23):S113–4.